Sex-, species-, and tissue-specific metabolism of empagliflozin in male mouse kidney forms an unstable hemiacetal metabolite (M466/2) that degrades to 4-hydroxycrotonaldehyde, a reactive and cytotoxic species

Chemical Research in Toxicology

Volumn 28, Issue 1, 2015, Pages 103-115

  Taub, Mitchell E ^a   Ludwig Schwellinger, Eva ^b   Ishiguro, Naoki ^c   Kishimoto, Wataru ^c   Yu, Hongbin ^a   Wagner, Klaus ^b   Tweedie, Donald ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCROTONALDEHYDE; CROTONALDEHYDE; CYTOTOXIC AGENT; EMPAGLIFLOZIN; GLUTATHIONE; ORGANIC ANION TRANSPORTER 3; PHENOL DERIVATIVE; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1A1; UNCLASSIFIED DRUG; ALDEHYDE; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; CYTOTOXIN; GLUCOSIDE; ORGANIC ANION TRANSPORTER; PENITRICIN B;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; ISOLATED KIDNEY; KIDNEY MICROSOME; LIVER MICROSOME; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; RAT; SEX DIFFERENCE; SINGLE DRUG DOSE; SPECIES DIFFERENCE; STOICHIOMETRY; TISSUE METABOLISM; ANIMAL; CHEMICALLY INDUCED; HEK293 CELL LINE; KIDNEY; KIDNEY DISEASE; LIVER; METABOLISM; MICROSOME; OOCYTE; WISTAR RAT; XENOPUS LAEVIS;

MUS; RATTUS; RATTUS NORVEGICUS;

ALDEHYDES; ANIMALS; BENZHYDRYL COMPOUNDS; CYTOTOXINS; FEMALE; GLUCOSIDES; HEK293 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; KIDNEY DISEASES; LIVER; MALE; MICE; MICROSOMES; OOCYTES; ORGANIC ANION TRANSPORTERS; RATS, WISTAR; SEX FACTORS; SPECIES SPECIFICITY; XENOPUS LAEVIS;

EID: 84922436119     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx500380t     Document Type: Article

References (39)

1. Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D. E., Bakker, R. A., Mark, M., Klein, T., and Eickelmann, P. (2012) Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors Diabetes Obes. Metab. 14, 83-90
2. Ferrannini, E., Seman, L., Seewaldt-Becker, E., Hantel, S., Pinnetti, S., and Woerle, H. J. (2013) A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes Diabetes Obes. Metab. 15, 721-728
3. Heise, T., Seewaldt-Becker, E., Macha, S., Hantel, S., Pinnetti, S., Seman, L., and Woerle, H. J. (2013) Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes Diabetes Obes. Metab. 15, 613-621
4. Bogdanffy, M. S., Stachlewitz, R. F., van Tongren, S., Knight, B., Sharp, D. E., Ku, W. W., Emeigh Hart, S., and Blanchard, K. (2014) Nonclinical safety of the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin Int. J. Toxicol. 10.1177/1091581814551648
5. EPAR, empagliflozin (2014) http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002677/WC500168592.pdf.
6. Shapiro, B. H., Agrawal, A. K., and Pampori, N. A. (1995) Gender differences in drug metabolism regulated by growth hormone Int. J. Biochem. Cell Biol. 27, 9-20
7. Buist, S. C. and Klaassen, C. D. (2004) Rat and mouse differences in gender-predominant expression of organic anion transporter (Oat1-3; Slc22a6-8) mRNA levels Drug Metab. Dispos. 32, 620-625
8. Martignoni, M., Groothuis, G. M., and de Kanter, R. (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction Expert Opin. Drug Metab. Toxicol. 2, 875-894
9. Breljak, D., Brzica, H., Sweet, D. H., Anzai, N., and Sabolic, I. (2013) Sex-dependent expression of Oat3 (Slc22a8) and Oat1 (Slc22a6) proteins in murine kidneys Am. J. Physiol. Renal Physiol. 304, F1114-F1126
10. Lee, W. S., Kanai, Y., Wells, R. G., and Hediger, M. A. (1994) The high affinity Na+/glucose cotransporter. Re-evaluation of function and distribution of expression J. Biol. Chem. 269, 12032-12039
11. Gorboulev, V., Schurmann, A., Vallon, V., Kipp, H., Jaschke, A., Klessen, D., Friedrich, A., Scherneck, S., Rieg, T., Cunard, R., Veyhl-Wichmann, M., Srinivasan, A., Balen, D., Breljak, D., Rexhepaj, R., Parker, H. E., Gribble, F. M., Reimann, F., Lang, F., Wiese, S., Sabolic, I., Sendtner, M., and Koepsell, H. (2012) Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion Diabetes 61, 187-196
12. Sabolic, I., Vrhovac, I., Eror, D. B., Gerasimova, M., Rose, M., Breljak, D., Ljubojevic, M., Brzica, H., Sebastiani, A., Thal, S. C., Sauvant, C., Kipp, H., Vallon, V., and Koepsell, H. (2012) Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences Am. J. Physiol. Cell Physiol. 302, C1174-C1188
13. Kojima, R., Sekine, T., Kawachi, M., Cha, S. H., Suzuki, Y., and Endou, H. (2002) Immunolocalization of multispecific organic anion transporters, OAT1, OAT2, and OAT3, in rat kidney J. Am. Soc. Nephrol. 13, 848-857
14. Ljubojevic, M., Herak-Kramberger, C. M., Hagos, Y., Bahn, A., Endou, H., Burckhardt, G., and Sabolic, I. (2004) Rat renal cortical OAT1 and OAT3 exhibit gender differences determined by both androgen stimulation and estrogen inhibition Am. J. Physiol. Renal Physiol. 287, F124-F138
15. Hagenbuch, B. and Meier, P. J. (2004) Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties Pfluegers Arch. 447, 653-665
16. Cheng, X., Maher, J., Chen, C., and Klaassen, C. D. (2005) Tissue distribution and ontogeny of mouse organic anion transporting polypeptides (Oatps) Drug Metab. Dispos. 33, 1062-1073
17. Jonker, J. W., Wagenaar, E., Van, E. S., and Schinkel, A. H. (2003) Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations Mol. Cell. Biol. 23, 7902-7908
18. Martovetsky, G., Tee, J. B., and Nigam, S. K. (2013) Hepatocyte nuclear factors 4alpha and 1alpha regulate kidney developmental expression of drug-metabolizing enzymes and drug transporters Mol. Pharmacol. 84, 808-823
19. Rinn, J. L., Rozowsky, J. S., Laurenzi, I. J., Petersen, P. H., Zou, K., Zhong, W., Gerstein, M., and Snyder, M. (2004) Major molecular differences between mammalian sexes are involved in drug metabolism and renal function Dev. Cell. 6, 791-800
20. Wang, X. J., Zhang, L., Byrne, D., Nummy, L., Weber, D., Krishnamurthy, D., Yee, N., and Senanayake, C. H. (2014) Efficient synthesis of empagliflozin, an inhibitor of SGLT-2, utilizing an AlCl-promoted silane reduction of a beta-glycopyranoside Org. Lett. 16, 4090-4093
21. Ishiguro, N., Saito, A., Yokoyama, K., Morikawa, M., Igarashi, T., and Tamai, I. (2005) Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney Drug Metab. Dispos. 33, 495-499
22. Phillips, J. A., Taub, M. E., Ishiguro, N., van Tongren, S., Knight, B., Ludwig-Schwellinger, E. C., Yuan, J., Smith, J. D., Yu, H., Escobar, P. A., Loging, W. T., and Ku, W. W. (2014) Mode of action and human relevance of male CD-1 mouse renal adenocarcinoma associated with lifetime exposure to empagliflozin Toxicologist 138, 576
23. Mugford, C. A. and Kedderis, G. L. (1998) Sex-dependent metabolism of xenobiotics Drug Metab. Rev. 30, 441-498
24. Mally, A. (2012) Ochratoxin a and mitotic disruption: mode of action analysis of renal tumor formation by ochratoxin A Toxicol. Sci. 127, 315-330
25. Tanaka, Y., Deguchi, Y., Ishii, I., and Terai, T. (1991) Sex differences in excretion of zenarestat in rat Xenobiotica 21, 1119-1125
26. Kato, Y., Kuge, K., Kusuhara, H., Meier, P. J., and Sugiyama, Y. (2002) Gender difference in the urinary excretion of organic anions in rats J. Pharmacol. Exp. Ther. 302, 483-489
27. Macha, S., Koenen, R., Sennewald, R., Schone, K., Hummel, N., Riedmaier, S., Woerle, H. J., Salsali, A., and Broedl, U. C. (2014) Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers Clin. Ther. 36, 280-290
28. Cui, J. Y., Renaud, H. J., and Klaassen, C. D. (2012) Ontogeny of novel cytochrome P450 gene isoforms during postnatal liver maturation in mice Drug Metab. Dispos. 40, 1226-1237
29. Sabolic, I., Asif, A. R., Budach, W. E., Wanke, C., Bahn, A., and Burckhardt, G. (2007) Gender differences in kidney function Pfluegers Arch. 455, 397-429
30. Yuan, J., Pande, P., Hill, J., Wang, Y., Hall, D., Mikl, J., and Ku, W. W. (2014) RNA-Seq reveals molecular changes in renal injury associated with exposure to empagliflozin in the male CD-1 mouse Toxicologist 138, 577
31. O'Brien, P. J., Siraki, A. G., and Shangari, N. (2005) Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health Crit. Rev. Toxicol. 35, 609-662
32. Stachulski, A. V., Baillie, T. A., Park, B. K., Obach, R. S., Dalvie, D. K., Williams, D. P., Srivastava, A., Regan, S. L., Antoine, D. J., Goldring, C. E., Chia, A. J., Kitteringham, N. R., Randle, L. E., Callan, H., Castrejon, J. L., Farrell, J., Naisbitt, D. J., and Lennard, M. S. (2013) The generation, detection, and effects of reactive drug metabolites Med. Res. Rev. 33, 985-1080
33. Uchida, K. (2003) 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress Prog. Lipid Res. 42, 318-343
34. Okuda, T. and Furumai, T. (1985) Penitricin, a new class of antibiotic produced by Penicillium aculeatum. IV. Biosynthesis J. Antibiot. (Tokyo) 38, 631-635
35. Smith, J. D., Huang, Z., Maw, H., Nardi, R., Foppiano, P., Her, L., Loging, W. T., Escobar, P. A., Phillips, J. A., Yu, H., Taub, M. E., and Ku, W. W. (2014) A predominant oxidative renal metabolite of empagliflozin in male mice is cytotoxic in mouse renal tubular cells but not genotoxic Toxicologist 138, 576
36. Knight, B., Emeigh Hart, S., Phillips, J. A., Koegler, S., Hall, J., and Ku, W. W. (2014) Pathogenesis of renal injury in the male CD-1 mouse associated with exposure to empagliflozin Toxicologist 138, 576-577
37. Fontaine, F. R., Dunlop, R. A., Petersen, D. R., and Burcham, P. C. (2002) Oxidative bioactivation of crotyl alcohol to the toxic endogenous aldehyde crotonaldehyde: association of protein carbonylation with toxicity in mouse hepatocytes Chem. Res. Toxicol. 15, 1051-1058
38. Liu, X. Y., Yang, Z. H., Pan, X. J., Zhu, M. X., and Xie, J. P. (2010) Crotonaldehyde induces oxidative stress and caspase-dependent apoptosis in human bronchial epithelial cells Toxicol. Lett. 195, 90-98
39. Ferrannini, E., Berk, A., Hantel, S., Pinnetti, S., Hach, T., Woerle, H. J., and Broedl, U. C. (2013) Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes Diabetes Care 36, 4015-4021